Mito-LND

SKU: orb1298278

Description

Mito-LND

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Neuroscience, Signal Transduction

Key Properties

• CAS Number: 2361564-49-8
• MW: 801.62
• Purity: 98.34% (May vary between batches)
• Formula: C₄₃H₄₅BrCl₂N₃OP
• SMILES: O=C(NCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=NN(CC5=CC=C(Cl)C=C5Cl)C6=C4C=CC=C6.[Br-]
• Target: OXPHOS|||Mitochondrial Metabolism|||Reactive Oxygen Species|||Autophagy
• Solubility: DMSO:45 mg/mL (56.14 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.49 mM)

Bioactivity

• In Vivo:
  Mito-LNDtreatment markedly enhanced potency against both lung cancer progression and metastasis. Mito-LND also decreases the rate of growth of A549 tumor xenografts. Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells.
  Read more...
• In Vitro:
  Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 of 0.74 μM and 0.69 μM, respectively. Mito-LND inhibits mitochondrial complex I and II activities with IC50 of 1.2 μM and 2.4 μM, respectively in H2030BrM3 cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells. Mito-LND decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

oxidative, p70S6K, Mitochondrial Metabolism, mitochondria, Mito LND, MitochondrialMetabolism, MitoLND, Mito-LND, Mito-Loidamine, Mito-Lonidamine, inhibit, mTOR, Inhibitor, Autophagy, anti-invasive, anti-cancer, AKT, oxidative phosphorylation (OXPHOS), ReactiveOxygenSpecies, Reactive Oxygen Species, phosphorylation

Compound Identifiers

PubChem CID

155977659